Business Recorder | More data backs Novartis' serelaxin in heart failure PMLiVE Momentum continues to build behind Novartis' heart failure candidate serelaxin, with new data from the European Society of Cardiology (ESC) meeting cementing its position as a blockbuster-in-waiting. A new analysis of data from the RELAX-AHF study has ... Novartis heart failure drug effective across patient groups Novartis' serelaxin (RLX030) improved symptoms and mortality across multiple ... Efficacy Of Novartis AG (ADR) (NYSE:NVS) For Heart Failures |
